Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 7417 - 7424 of 12030 results
Grassley Continues To Press CMS on Medicaid Drug Rebate Classifications: What Will Be the Fallout?
January 12, 2017| Blog| Viewpoint
10 Years Out, Report Says Recession's Impact on Firms is Clear
January 12, 2017| News
Pizza! Pizza!: Little Caesar’s Repeated Term Slogans Are Not a “Family of Marks”
January 12, 2017| Blog| Viewpoint
FDA Finalizes Tobacco Product Intended Use Rules, Under a Risk of Rescission by Congress
January 12, 2017| Blog| Viewpoint
The Future of the ACA Week 5: The Rep. Tom Price Plan(s)
January 11, 2017| Blog| Viewpoint
Beyond the Eleventh Hour: FDA Prepares to Finalize Intended Use Amendments Despite Midnight Rule Relief Act
January 11, 2017| Blog| Viewpoint
U.S. Supreme Court to Hear Arguments on January 18, 2017 in "The Slants" Case.
January 11, 2017| Blog| Viewpoint
Lazard Annual Report Reveals Steady Decline in Costs of Clean Energy Technologies
January 10, 2017| Blog| Viewpoint
News & Press Releases
San Francisco Business Times featured Mintz’s new office lease in San Francisco at 525 Market St. The firm will be increasing its footprint in downtown by 50% to 29,000 square feet on a whole single floor with the new space.
Mintz advised the underwriters in connection with a $230 million public offering by Cogent Biosciences, Inc. of 25,555,556 shares of common stock, which includes 3,333,333 shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering were approximately $230 million, including proceeds from the exercise in full by the underwriters of the option to purchase additional shares, before deducting underwriting discounts and commissions and other offering expenses.
Mintz advised the underwriters in connection with a $200 million public offering by Soleno Therapeutics, Inc. of 2,352,941 shares of its common stock at a price to the public of $85.00 per share. The gross proceeds to Soleno from the offering were approximately $200 million before deducting underwriting discounts and commissions and other offering expenses. In addition, Soleno granted the underwriters a 30-day option to purchase up to an additional 352,941 shares of its common stock at the public offering price.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|